Clinical trial title
|
Description
|
Status |
Location |
MNDRIA
investment |
Phase 2/3 Cu(II)ATSM: A phase 2/3 clinical trial of copper-ATSM (CuATSM) for the treatment of MND progression will soon begin in Australia. This trial will be administered through Macquarie University in Sydney.
More information is available on our FAQ page. |
This trial follows on from the succesful completion of a phase 1 clinical trial, which identified a safe dosage. More information is available here. |
Recruitment will soon begin. |
Study being coordinated by Macquarie University. Please contact your neurologist for more information. |
More than $1.2 million to support 3 projects that aim to develop copper-ATSM as a potential therapeutic |
Environmental risk factors for MND: Scientists at Macquarie University are searching to find the causes of MND. As part of this research, data and biological samples are being sought for the Neurodegenerative Disease Biobank. |
This study aims to screen for environmental risk factors and their potential association with MND in Australia, specifically in the agricultural Riverina Region. A number of groups are being sought from the region: patients with an MND diagnosis; people living in the same household as a person diagnosed with MND in the last ten years; or people who have lived in the region for at least ten years in the past, but have since moved away. All participants will be required to provide a urine sample and answer a questionnaire. |
Active, recruiting patients and controls. |
Study being coordinated by Macquarie University.
Email Susan D'Silva or call
(02) 9812 3741
More information |
|
A survey of healthcare professionals on the measurement of physical functioning in ALS/MND and attitudes to the development of technology based measurement and monitoring solutions. |
Emerging technologies provide opportunities for development of novel solutions for assessment and remote monitoring of physical functioning in people with ALS/MND. This study is looking at the perspectives of health professionals regarding the potential of new technologies to replace or augment current assessment methods. This study involves an online survey of healthcare professionals working with ALS/MND internationally. |
Active, recruiting healthcare professionals. |
An international study coordinated by Dr Deirdre Murray at Trinity College in Dublin.
Click here for more information. |
|
DEALS (Diet and Exercise in ALS) Study - The effects of active exercise combined with an enriched diet on swallowing, speech function and weight in patients with MND; a randomised trial.
More information. |
This clinical trial is evaluating the effects of diet changes in patients with MND combined with active exercising on swallowing function, speech and weight status. |
Final stages of recruitment |
Sydney
University
Contact Professor Vicki Flood if you would like to be involved in this trial. |
This clinical trial is partly supported by MNDRIA |
EMERALD: A randomised, double-blind, single-centre Phase 3 study on the safety, tolerability and efficacy of Cannabis Based Medicine Extract (CannTrust CBD Oil) in slowing the disease progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease patients (EMERALD).
More information |
Participants will be assigned by chance to receive either medicinal cannabis or placebo. Treatment will continue for 180 days and participants will be seen every 3 months in the research clinic, with a monthly telephone call in between. See our FAQ page for more information. |
Active, recruiting patients. |
Gold Coast University Hospital.
Click here for more information on eligibility and for contact information. |
|
South Western Sydney Local Health District (SWSLHD) Communication and Assistive Technology (CAT) Clinic Research Study
Liverpool Hospital (Sydney) offers a state of the art Communication and Assistive Technology Clinic for those diagnosed with MND and living within the SWSLHD.
More information. |
This project aims to identify if assessment and intervention within the Communication and Assistive Technology Clinic within 12 months of diagnosis improves quality of life, function and decreases carer burden. Participants will complete surveys and interviews in addition to standard care by specialised Occupational and Speech Pathologists. See our FAQ page for more information. |
Active, recruiting patients. |
Liverpool Hospital, Sydney.
See here for more information on eligibilityy and for contact information. |
|
Breath-stacking:
Lung volume recruitment in neuromuscular disease: Can ‘breath-stacking’ improve lung function, respiratory symptoms and quality of life for people with neuromuscular disease?
> more information |
This clinical trial is comparing breath-stacking breathing exercises to
diaphragmatic breathing exercises in people with neuromuscular disease including people with MND to see which treatment is more effective. See our FAQ page for more information. |
Active, recruiting patients. |
Melbourne |
This clinical trial is partly supported by MNDRIA |
REFALS:
Effects of Oral levosimendan (ODM-109) on Respiratory Function in Patients with ALS.
more information |
The primary objective of this Phase 3 study is to confirm that levosimendan can significantly improve respiratory function measured by supine slow vital capacity (SVC) in amyotrophic lateral sclerosis (ALS) patients.
The secondary objective is to confirm that levosimendan improves the functionality of subjects, using sleep scales to assess daytime somnolence and sleep quality. In addition, the long-term tolerability and safety of levosimendan in ALS patients will be evaluated, assessing up to 48 weeks of exposure. See our FAQ page for more information. |
Active, recruiting patients. |
Sydney, Brisbane, Adelaide, Melbourne, Perth.
Contact your MND clinic or neurologist for more information on participating in this trial. |
|
Phase 2 Triumeq Complete:
Safety and tolerability of antiretroviral (Triumeq) in patients with amyotrophic lateral sclerosis (ALS) (The Lighthouse Project)
> more information |
The Lighthouse Project is a trial to test an antiretroviral therapy called Triumeq, following research which suggests that a virus may be a cause or trigger for ALS. See our Grants Awarded in 2019 page for information on the upcoming Phase 3 trial of Triumeq. |
Phase 2 trial complete. |
Sydney, Melbourne |
This clinical trial is partly supported by MNDRIA |
BreatheMND-1:
A prospective study to assess the causes and treatment of sleep disordered breathing and respiratory failure in patients with MND.
More information.
|
This clinical trial is investigating patterns of abnormal breathing and tailoring targeted treatment to improve breathing, quality of life, sleep and survival in patients with MND. This includes assessing the effect of two different settings of non-invasive ventilation, respiratory support delivered by a mask and machine, by using a new “smart” ventilator. |
Active, not recruiting |
Adelaide |
This clinical trial is partly supported by MNDRIA |
TEALS (Tecfidera in amyotrophic lateral sclerosis) Study:
A multi-centre Phase 2 clinical trial to investigate the safety, tolerability and effectiveness of Tecfidera in people with MND. More information. |
This clinical trial will assess if Tecfidera is effective in slowing down disease progression and whether it is safe in MND patients. See our FAQ page for more information. |
Recruitment completed |
Adelaide, Brisbane, Melbourne,
Sydney, Perth |
|
FORTITUDE-ALS is a phase 2 clinical trial which is designed to evaluate whether reldesemtiv (also known as CK-2127107) has an effect on participants with ALS/MND and what kind of side effects may occur.
More information. |
Reldesemtiv is an investigational medicine that is being evaluated as a potential new medicine which could slow the decline of skeletal muscle function in diseases and conditions associated with muscle weakness or fatigue such as ALS/MND. May 2019 Phase 2 results now availailble here. |
Active, not recruiting. |
Sydney, Brisbane, Adelaide, Perth. |
|